Cti Biopharma Corp Stock Current Valuation
| CTICDelisted Stock | USD 9.09 0.00 0.00% |
Valuation analysis of CTi Biopharma Corp helps investors to measure CTi Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that CTi Biopharma's price fluctuation is very steady at this time. Calculation of the real value of CTi Biopharma Corp is based on 3 months time horizon. Increasing CTi Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since CTi Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CTi Stock. However, CTi Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.09 | Real 6.66 | Hype 9.09 |
The real value of CTi Stock, also known as its intrinsic value, is the underlying worth of CTi Biopharma Corp Company, which is reflected in its stock price. It is based on CTi Biopharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of CTi Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of CTi Biopharma Corp helps investors to forecast how CTi stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CTi Biopharma more accurately as focusing exclusively on CTi Biopharma's fundamentals will not take into account other important factors: CTi Biopharma Corp Company Current Valuation Analysis
CTi Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current CTi Biopharma Current Valuation | 1.26 B |
Most of CTi Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CTi Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, CTi Biopharma Corp has a Current Valuation of 1.26 B. This is 91.24% lower than that of the Biotechnology sector and 72.92% lower than that of the Health Care industry. The current valuation for all United States stocks is 92.43% higher than that of the company.
CTi Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CTi Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CTi Biopharma could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics of similar companies.CTi Biopharma is currently under evaluation in current valuation category among its peers.
CTi Fundamentals
| Return On Equity | -10.19 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (0.91) % | |||
| Operating Margin | (0.74) % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 131.88 M | |||
| Shares Owned By Insiders | 5.49 % | |||
| Shares Owned By Institutions | 83.28 % | |||
| Number Of Shares Shorted | 11.27 M | |||
| Price To Earning | (1.68) X | |||
| Price To Book | 112.63 X | |||
| Price To Sales | 22.01 X | |||
| Revenue | 53.95 M | |||
| Gross Profit | 50.43 M | |||
| EBITDA | (79.85 M) | |||
| Net Income | (92.99 M) | |||
| Cash And Equivalents | 81.64 M | |||
| Cash Per Share | 0.64 X | |||
| Total Debt | 49.96 M | |||
| Current Ratio | 3.26 X | |||
| Book Value Per Share | (0.19) X | |||
| Cash Flow From Operations | (81.19 M) | |||
| Short Ratio | 1.08 X | |||
| Earnings Per Share | (0.54) X | |||
| Target Price | 10.05 | |||
| Number Of Employees | 127 | |||
| Beta | 0.83 | |||
| Market Capitalization | 1.2 B | |||
| Total Asset | 125.92 M | |||
| Retained Earnings | (2.52 B) | |||
| Working Capital | 18.26 M | |||
| Current Asset | 134.97 M | |||
| Current Liabilities | 72.41 M | |||
| Z Score | -15.1 | |||
| Net Asset | 125.92 M |
About CTi Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CTi Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CTi Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CTi Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |